It is simple. Antibiotics are designed to be used on a limited basis for only a few days or weeks. When the bacteria is eliminated, the treatment ends. Why invest hundreds of millions of dollars into a new type antibiotic when other drugs that are used for chronic disease are so much more profitable?
As of 2013, Pfizer was the only drug company still actively developing new antibiotics. Meanwhile, resistant bacteria a outpacing the research. There are now some strains of bacteria that are virtually untreatable. There are few new antibiotics because it's not profitable to invest in those drugs.
When do we abandon the market-based healthcare model - after the next Black Plague - assuming we survive, that is?
Quote
And from an economic standpoint of a developer, that means you’re not— you’re not getting the return on the investment you’ve made because you’ve spent between $600 million and a billion dollars to bring that new antibiotic to market.
DAVID E. HOFFMAN: Wait. You mean it costs up to a billion dollars to bring a new drug to market?
Dr. JOHN REX: It can easily cost up to a billion dollars to bring a new drug to the market. And the initial reaction to it is, “That’s great, and let’s not use it. Let’s use it as little as possible.”
Dr. BRAD SPELLBERG: So here’s a large company saying, “I have— I can make billions off cholesterol drugs, blood pressure drugs, arthritis drugs, dementia, things that I know patients are going to have to take every day for the rest of their lives. Why would I put my R&D dollars into the antibiotic division, that isn’t going to make me any money, when I can put it over here, that’s going to make a lot of money for the company? I answer to the shareholders.”